We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+13.94%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$284M
AUM Growth
+$26.8M
Cap. Flow
+$26.8M
Cap. Flow %
9.46%
Top 10 Hldgs %
45.99%
Holding
71
New
15
Increased
14
Reduced
11
Closed
6

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.32M
2
SHPG
Shire pic
SHPG
+$4.62M
3
EXEL icon
Exelixis
EXEL
+$4.15M
4
TSRO
TESARO, Inc.
TSRO
+$4.15M
5
STML
Stemline Therapeutics, Inc.
STML
+$4.15M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$5.75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$4.98M
3
CALA
Calithera Biosciences, Inc
CALA
+$2.95M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$2.4M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
2 Miscellaneous 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$3.36M 1.18%
1,505,804
+533,882
+55% +$1.33M
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$3.14M 1.11%
322,436
– –
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$3.08M 1.08%
57,500
– –
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.03M 1.07%
185,000
-88,000
-32% -$1.31M
DERM
30
DELISTED
Dermira, Inc.
DERM
$3M 1.06%
108,000
– –
NBIX icon
31
Neurocrine Biosciences
NBIX
$15.8B
$2.87M 1.01%
37,000
-29,000
-44% -$1.98M
IONS icon
32
Ionis Pharmaceuticals
IONS
$10.4B
$2.59M 0.91%
51,500
– –
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.53M 0.89%
115,500
+29,000
+34% +$933K
MTEM
34
DELISTED
Molecular Templates, Inc.
MTEM
$2.48M 0.87%
16,506
+13,297
+414% +$1.67M
FOMX
35
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.3M 0.81%
+382,838
New +$2.3M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.29M 0.81%
+25,000
New +$1.43M
JUNO
37
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.28M 0.81%
50,000
-13,000
-21% -$648K
AKAO
38
DELISTED
Achaogen Inc
AKAO
$2.2M 0.77%
204,538
+130,000
+174% +$1.63M
AVXS
39
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.88M 0.66%
17,000
– –
DCPH
40
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.75M 0.62%
77,000
+52,000
+208% +$1.02M
ANAB icon
41
AnaptysBio
ANAB
$1.7B
$1.71M 0.6%
+17,000
New +$1.25M
ASXC
42
DELISTED
Asensus Surgical, Inc.
ASXC
$1.71M 0.6%
68,391
– –
SRPT icon
43
Sarepta Therapeutics
SRPT
$2.28B
$1.5M 0.53%
27,000
-94,000
-78% -$4.98M
KYNB
44
Kyntra Bio
KYNB
$32.4M
$1.49M 0.52%
1,256
– –
CBAY
45
DELISTED
Cymabay Therapeutics
CBAY
$1.33M 0.47%
+145,000
New +$1.24M
GWPH
46
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.27M 0.45%
+9,600
New +$1.13M
OPTN
47
DELISTED
OptiNose
OPTN
$1.23M 0.43%
+4,333
New +$1.22M
PBYI icon
48
Puma Biotechnology
PBYI
$477M
$1.19M 0.42%
+12,000
New +$1.34M
PTLA
49
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.17M 0.41%
24,000
– –
RSLS
50
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$1.15M 0.41%
+375
New +$1.24M
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2017 Portfolio in Review

As of Q4 2017, International Biotechnology Trust held 71 positions worth $284M, up 10% from $257M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

International Biotechnology Trust deployed $26.8M of net new capital in Q4 2017, opening 15 new positions and adding to 14 existing holdings. Its largest new stake was Nektar Therapeutics: 14,067 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $4.98M trimmed.

  • International Biotechnology Trust's largest Q4 2017 buy was Nektar Therapeutics: 14,067 shares worth $12.6M.
  • International Biotechnology Trust added most to Exelixis in Q4 2017, an estimated $4.15M increase.
  • International Biotechnology Trust's biggest Q4 2017 reduction was Sarepta Therapeutics, cutting an estimated $4.98M.
  • International Biotechnology Trust fully exited Acceleron Pharma in Q4 2017, selling an estimated $5.75M.
  • International Biotechnology Trust's ten largest holdings make up 46% of its $284M portfolio in Q4 2017.
  • International Biotechnology Trust opened 15 new positions and closed 6 in Q4 2017.
  • International Biotechnology Trust's portfolio value rose 10% quarter-over-quarter to $284M.

Based on International Biotechnology Trust's 13F filing for Q4 2017, filed 2 Mar 2018.